EUVIMEDEUVIMED entdecken
Crossref

Tackling Esophageal Squamous Cell Carcinoma with ITFn‐Pt(IV): A Novel Fusion of PD‐L1 Blockade, Chemotherapy, and T‐cell Activation

Qi Xin, Daji Wang, Shenghui Wang, Lirong Zhang, Qian Liang, Xiyun Yan, Kelong Fan iD, Bing Jiang iD

Advanced Healthcare Materials · 2024-04 · 13 (11)

DOI: 10.1002/adhm.202303623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 31.12.2023. Verfasst von Qi Xin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nanozyme Medical Center, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, T-Lymphocytes, B7-H1 Antigen, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PD‐1/PD‐L1 blockade immunotherapy has gained approval for the treatment of a diverse range of tumors; however, its efficacy is constrained by the insufficient infiltration of T lymphocytes into the tumor microenvironment, resulting in suboptimal patient responses. Here, a pioneering immunotherapy ferritin nanodrug delivery system denoted as ITFn‐Pt(IV) is introduced. This system orchestrates a synergistic fusion of PD‐L1 blockade, chemotherapy, and T‐cell activation, aiming to augment the efficacy of tumor immunotherapy. Leveraging genetic engineering approach and temperature‐regulated channel‐based drug loading techniques, the architecture of this intelligent responsive system is refined. It is adept at facilitating the precise release of T‐cell activating peptide Tα1 in the tumor milieu, leading to an elevation in T‐cell proliferation and activation. The integration of PD‐L1 nanobody KN035 ensures targeted engagement with tumor cells and mediates the intracellular delivery of the encapsulated Pt(IV) drugs, culminating in immunogenic cell death and the subsequent dendritic cell maturation. Employing esophageal squamous cell carcinoma (ESCC) as tumor model, the potent antitumor efficacy of ITFn‐Pt(IV) is elucidated, underscored by augmented T‐cell infiltration devoid of systemic adverse effects. These findings accentuate the potential of ITFn‐Pt(IV) for ESCC treatment and its applicability to other malignancies resistant to established PD‐1/PD‐L1 blockade therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsT-LymphocytesB7-H1 AntigenEsophageal Squamous Cell CarcinomaAnimalsHumansMiceCell Line, TumorLymphocyte ActivationFerritinsTumor MicroenvironmentImmunotherapyAntineoplastic AgentsNanoparticlesDrug Delivery Systems

Stichwörter der Autor:innen

PD‐1/PD‐L1 blockadeT‐cell activationbioengineered ferritin nanocageesophageal squamous cell carcinomaimmunogenic death

Substanzen

B7-H1 AntigenFerritinsAntineoplastic Agents

Autor:innen und Institutionen

  • Nanozyme Medical Center, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
  • Nanozyme Synthesis Center, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
  • State Key Laboratory of Esophageal Cancer Prevention & Treatment, Henan, 450001, China.
  • CAS Engineering Laboratory for Nanozyme, Key Laboratory of Biomacromolecules (CAS), CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
  • Nanozyme Laboratory in Zhongyuan, Zhengzhou, Henan, 451163, China.

ORCID-Profile: Kelong Fan, Bing Jiang

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation
  • Postdoctoral Research Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Science and Technology Program for Basic Research in Shenzhen
  • Grant for International Joint Research Project of the Institute of Medical Science, the University of Tokyo

Zitieren

APA

Xin, Q., Wang, D., Wang, S., Zhang, L., Liang, Q., Yan, X., Fan, K., & Jiang, B. (2024). Tackling Esophageal Squamous Cell Carcinoma with ITFn‐Pt(IV): A Novel Fusion of PD‐L1 Blockade, Chemotherapy, and T‐cell Activation. Advanced Healthcare Materials, 13(11). https://doi.org/10.1002/adhm.202303623

Vancouver

Xin Q, Wang D, Wang S, Zhang L, Liang Q, Yan X, et al. Tackling Esophageal Squamous Cell Carcinoma with ITFn‐Pt(IV): A Novel Fusion of PD‐L1 Blockade, Chemotherapy, and T‐cell Activation. Advanced Healthcare Materials. 2024;13(11). doi:10.1002/adhm.202303623

BibTeX
@article{Xin2024,
  author = {Xin, Qi and Wang, Daji and Wang, Shenghui and Zhang, Lirong and Liang, Qian and Yan, Xiyun and Fan, Kelong and Jiang, Bing},
  title = {Tackling Esophageal Squamous Cell Carcinoma with ITFn‐Pt(IV): A Novel Fusion of PD‐L1 Blockade, Chemotherapy, and T‐cell Activation},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {11},
  doi = {10.1002/adhm.202303623}
}
Kostenlos starten →